呼吸內科5 篇

影響力 3

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

發表日期: 2026-04-01

Lung cancer (Amsterdam, Netherlands)

MediLens 收錄日: 2026-04-02

This phase II trial evaluated the efficacy of osimertinib in patients with EGFR-mutated non-small cell lung cancer, focusing on those with untreated brain metastases. The study included 100 patients, showing an overall objective response rate of 72.0%, with 81.8% in those with measurable brain me...

在PubMed上閱讀

影響力 3

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.

發表日期: 2026-04-01

Lung cancer (Amsterdam, Netherlands)

MediLens 收錄日: 2026-04-02

The study evaluated the overall survival (OS) of amivantamab-lazertinib compared to osimertinib in Asian patients with untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC). Results showed a significant improvement in OS for amivantamab-lazertinib, with a hazard ratio of 0.74 at a me...

在PubMed上閱讀

影響力 3

Defining response-adapted surgery after neoadjuvant systemic therapy in sinonasal squamous cell carcinoma.

發表日期: 2026-04-01

Oral oncology

MediLens 收錄日: 2026-04-02

This study presents a novel classification system for documenting surgical outcomes in patients with sinonasal squamous cell carcinoma (SCC) undergoing neoadjuvant therapy. The framework addresses the complexities of sinonasal anatomy and aims to standardize the evaluation of surgical morbidity a...

在PubMed上閱讀

影響力 3

Xbp1-driven lipid metabolism promotes immunosuppression in lung cancer: Jianpi Chutan Jiedu formula reshapes metabolic-immune crosstalk.

發表日期: 2026-04-01

Phytomedicine : international journal of phytotherapy and phytopharmacology

MediLens 收錄日: 2026-04-02

This study investigates the antitumor efficacy of the Jianpi Chutan Jiedu Formula (JCJ) in lung cancer (LC) and its underlying mechanisms. It identifies high expression of XBP1 in LC and demonstrates that Xbp1 overexpression leads to lipid accumulation and immunosuppression in the tumor microenvi...

在PubMed上閱讀

影響力 3

Pediatric Invasive Group A Streptococcus Infections with Central Nervous System Involvement: A Single Institution Case Series in Southern New England.

發表日期: 2026-04-01

Rhode Island medical journal (2013)

MediLens 收錄日: 2026-04-02

This case series highlights three rare pediatric cases of invasive Group A Streptococcus (iGAS) infections with central nervous system involvement, all occurring within a two-month period in Massachusetts. The patients presented with severe conditions, including meningitis and subdural collection...

在PubMed上閱讀

醫學研究趨勢

呼吸內科5 篇

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.

Defining response-adapted surgery after neoadjuvant systemic therapy in sinonasal squamous cell carcinoma.

Xbp1-driven lipid metabolism promotes immunosuppression in lung cancer: Jianpi Chutan Jiedu formula reshapes metabolic-immune crosstalk.

Pediatric Invasive Group A Streptococcus Infections with Central Nervous System Involvement: A Single Institution Case Series in Southern New England.

獲取個人化每日摘要